Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (24569)
All Articles published online
|
Apr 14, 2011 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lim R, Sun Y, Im SA, Hsieh RK, Yau TK, Bonaventura A, Cheirsilpa A, Esser R, Mueser M, Advani S. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study. World J Gastroenterol 2011; 17(14): 1879-1888 [PMID: 21528063 DOI: 10.3748/wjg.v17.i14.1879] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i14/1879.htm |
| Number | Citing Articles |
| 1 |
Michael B. Tomblyn, Bryan H. Goldman, Charles R. Thomas, Jacqueline K. Benedetti, Heinz-Josef Lenz, Vivek Mehta, Thaddeus Beeker, Philip J. Gold, James L. Abbruzzese, Charles D. Blanke. Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414). Journal of Thoracic Oncology 2012; 7(5): 906 doi: 10.1097/JTO.0b013e31824c7bed
|
| 2 |
Richard M. Goldberg, Clara Montagut, Zev A. Wainberg, Philippe Ronga, Françis Audhuy, Julien Taieb, Sebastian Stintzing, Salvatore Siena, Daniele Santini. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open 2018; 3(4): e000353 doi: 10.1136/esmoopen-2018-000353
|
| 3 |
C.F. Jehn, L. Böning, H. Kröning, A. Pezzutto, D. Lüftner. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. European Journal of Cancer 2014; 50(7): 1269 doi: 10.1016/j.ejca.2014.01.005
|
| 4 |
Robert J. Cersosimo. Management of advanced colorectal cancer, part 2. American Journal of Health-System Pharmacy 2013; 70(6): 491 doi: 10.2146/ajhp110532b
|
| 5 |
Benny Vittrup Jensen, Jakob V. Schou, Mette Yilmaz, Helle H. Johannesen, Kristin Skougaard, Dorte Linnemann, Estrid V. Hogdall, Finn O. Larsen, Julia S. Johansen, Per Pfeiffer, Dorte L. Nielsen. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. International Journal of Cancer 2021; 148(10): 2542 doi: 10.1002/ijc.33448
|
| 6 |
Florinda A. Santos, Rui Manuel Reis, Lucas C. Barroti, Allan A. L. Pereira, Marcus M. Matsushita, Ana Carolina de Carvalho, José Guilherme Datorre, Gustavo N. Berardinelli, Raphael L. C. Araujo. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer 2023; doi: 10.1007/s12029-023-00964-x
|
| 7 |
Zev A. Wainberg, Maria Alsina, Heloisa P. Soares, Irene Braña, Carolyn D. Britten, Gianluca Del Conte, Patrick Ezeh, Brett Houk, Kenneth A. Kern, Stephen Leong, Nuzhat Pathan, Kristen J. Pierce, Lillian L. Siu, Jennifer Vermette, Josep Tabernero. A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted Oncology 2017; 12(6): 775 doi: 10.1007/s11523-017-0530-5
|
| 8 |
D. Gomez, A. De Rosa, A. Addison, A. Brooks, H.Z. Malik, I.C. Cameron. Cetuximab therapy in the treatment of metastatic colorectal cancer: The future frontier?. International Journal of Surgery 2013; 11(7): 507 doi: 10.1016/j.ijsu.2013.04.014
|
| 9 |
Dong Ju Son, Ji Eun Hong, Jung Ok Ban, Ju Ho Park, Hye Lim Lee, Sun Mi Gu, Jae Yeon Hwang, Myung Hee Jung, Dong Won Lee, Sang-Bae Han, Jin Tae Hong. Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell GrowthviaInhibition of the ERK-Dependent EGF Receptor Signaling Pathway. BioMed Research International 2015; 2015: 1 doi: 10.1155/2015/397563
|
| 10 |
Carsten Bokemeyer, Fortunato Ciardiello, Olivier Dubreuil, Joel Guigay, Stefan Kasper, Per Pfeiffer, Carmine Pinto, Kensei Yamaguchi, Takayuki Yoshino, Christoph Zielinski, Regina Esser, Josep Tabernero. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. Future Oncology 2024; 20(7): 393 doi: 10.2217/fon-2023-0282
|
| 11 |
S. Abdelwahab, A. Azmy, H. Abdel-aziz, H. Salim, A. Mahmoud. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). Journal of Cancer Research and Clinical Oncology 2012; 138(9): 1487 doi: 10.1007/s00432-012-1229-8
|
| 12 |
Gerald W. Prager, Matthias Unseld, Fredrik Waneck, Robert Mader, Fritz Wrba, Markus Raderer, Thorsten Fuereder, Phillip Staber, Ulrich Jäger, Markus Kieler, Daniela Bianconi, Mir Alireza Hoda, Lukas Baumann, Alexander Reinthaller, Walter Berger, Christoph Grimm, Heinz Kölbl, Maria Sibilia, Leonhard Müllauer, Christoph Zielinski. Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology. Oncotarget 2019; 10(9): 942 doi: 10.18632/oncotarget.26604
|
| 13 |
Suzannah J Chapman, Daniel McKavanagh, Matthew E Burge, Ian McPherson, Euan Walpole, Samantha A Hollingworth. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland. Asia-Pacific Journal of Clinical Oncology 2017; 13(5) doi: 10.1111/ajco.12518
|
| 14 |
Jesús García-Foncillas, Yu Sunakawa, Dan Aderka, Zev Wainberg, Philippe Ronga, Pauline Witzler, Sebastian Stintzing. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00849
|
| 15 |
Hao Zhuang, Zhen-yi Xue, Lu Wang, Xiao-yan Li, Ning Zhang, Rong-xin Zhang. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer. Clinical Oncology and Cancer Research 2011; 8(4): 207 doi: 10.1007/s11805-011-0582-8
|